1
|
Gégout Petit A, Jeulin H, Legrand K, Jay N, Bochnakian A, Vallois P, Schvoerer E, Guillemin F. Seroprevalence of SARS-CoV-2, Symptom Profiles and Sero-Neutralization in a Suburban Area, France. Viruses 2021; 13:v13061076. [PMID: 34200070 PMCID: PMC8230202 DOI: 10.3390/v13061076] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2021] [Revised: 05/29/2021] [Accepted: 06/01/2021] [Indexed: 01/28/2023] Open
Abstract
The World Health Organisation recommends monitoring the circulation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We investigated anti-SARS-CoV-2 total immunoglobulin (IgT) antibody seroprevalence and in vitro sero-neutralization in Nancy, France, in spring 2020. Individuals were randomly sampled from electoral lists and invited with household members over 5 years old to be tested for anti-SARS-CoV-2 (IgT, i.e., IgA/IgG/IgM) antibodies by ELISA (Bio-rad); the sero-neutralization activity was evaluated on Vero CCL-81 cells. Among 2006 individuals, the raw seroprevalence was 2.1% (95% confidence interval 1.5 to 2.9), was highest for 20- to 34-year-old participants (4.7% (2.3 to 8.4)), within than out of socially deprived area (2.5% vs. 1%, p = 0.02) and with than without intra-family infection (p < 10-6). Moreover, 25% of participants presented at least one COVID-19 symptom associated with SARS-CoV-2 positivity (p < 10-13), with highly discriminant anosmia or ageusia (odds ratio 27.8 [13.9 to 54.5]); 16.3% (6.8 to 30.7) of seropositive individuals were asymptomatic. Positive sero-neutralization was demonstrated in vitro for 31/43 seropositive subjects. Regarding the very low seroprevalence, a preventive effect of the lockdown in March 2020 can be assumed for the summer, but a second COVID-19 wave, as expected, could be subsequently observed in this poorly immunized population.
Collapse
Affiliation(s)
- Anne Gégout Petit
- IECL, Université de Lorraine, CNRS, Inria, F-54000 Nancy, France; (A.G.P.); (P.V.)
| | - Hélène Jeulin
- LCPME, Université de Lorraine, CNRS, F-54000 Nancy, France;
- Laboratoire de Virologie, CHRU de Nancy Brabois, F-54500 Vandoeuvre-lès-Nancy, France
- Correspondence: ; Tel.: +33-383-153-467
| | - Karine Legrand
- CIC Epidémiologie Clinique, CHRU-Nancy, Inserm, Université de Lorraine, F-54000 Nancy, France; (K.L.); (A.B.); (F.G.)
| | - Nicolas Jay
- LORIA, CHRU-Nancy, Université de Lorraine, CNRS, Inria, LORIA, F-54000 Nancy, France;
| | - Agathe Bochnakian
- CIC Epidémiologie Clinique, CHRU-Nancy, Inserm, Université de Lorraine, F-54000 Nancy, France; (K.L.); (A.B.); (F.G.)
| | - Pierre Vallois
- IECL, Université de Lorraine, CNRS, Inria, F-54000 Nancy, France; (A.G.P.); (P.V.)
| | - Evelyne Schvoerer
- LCPME, Université de Lorraine, CNRS, F-54000 Nancy, France;
- Laboratoire de Virologie, CHRU de Nancy Brabois, F-54500 Vandoeuvre-lès-Nancy, France
| | - Francis Guillemin
- CIC Epidémiologie Clinique, CHRU-Nancy, Inserm, Université de Lorraine, F-54000 Nancy, France; (K.L.); (A.B.); (F.G.)
| |
Collapse
|
2
|
Abstract
Heart failure (HF) symptoms are known to influence depressive symptoms, yet a symptom profile has not been identified. HF symptoms relative to symptom experience (frequency, severity, interference with physical activity and enjoyment of life) associated with depressive symptoms were examined. Data from three HF studies (N = 308) which used the Heart Failure Symptom Survey were included in this cross-sectional secondary analysis. Supervised classification for and identification of symptoms most associated with depressive symptoms were accomplished using random forest algorithms via conditional inference trees. The HF symptom profile associated with depressive symptoms across all four symptom experience domains included fatigue, dizziness, and forgetfulness/difficulty concentrating. Abdominal bloating, worsening cough, and difficulty sleeping were also important, but did not consistently rank in the top 5 for symptom importance relative to all symptom experience domains. Symptom profiling may enhance early identification of patients at risk for depressive symptoms and inform symptom management interventions.
Collapse
|